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Context:TheGHreceptor(GHR)pseudoexon6defectisafrequentcauseofGHinsensitivity(GHI)
resultingfromanon-functioningGHreceptor(GHR).Itresultsinabroadrangeofphenotypesand
may also be present in patients diagnosed as idiopathic short stature.
Objective: Our objective was to correct aberrant GHR splicing and inclusion of 6 using exon-
skipping antisense oligonucleotides (ASOs).
Design and Setting: Three ASOs binding the 5 (ASO-5), 3 (ASO-3), and branch site (ASO-Br) of 6
were tested in an in vitro splicing assay and a cell transfection system. The wild-type (wt) and
mutant (mt) DNA minigenes (wt- and mtL1-GHR6-L2, respectively) were created by inserting the
GHR 6 in a well-characterized splice reporter (Adml-par). For the in vitro splicing assay, the wt-
and mtL1-GHR6-L2 were transcribed into pre-mRNA in the presence of [
32P]GTP and incubated
with ASOs in HeLa nuclear extracts. For the cell transfection studies, wt- and mtL1-GHR6-L2
clonedintopcDNA3.1weretransfectedwithASOsintoHEK293cells.After48h,RNAwasextracted
and radiolabeled RT-PCR products quantified.
Results: ASO-3 induced an almost complete pseudoexon skipping in vitro and in HEK293 cells. This
effect was dose dependent and maximal at 125–250 nM. ASO-5 produced modest pseudoexon
skipping, whereas ASO-Br had no effect. Targeting of two splice elements simultaneously was less
effective than targeting one. ASO-Br was tested on the wtL1-GHR6-L2 and did not act as an
enhancer of 6 inclusion.
Conclusions: The exon-skipping ASO approach was effective in correcting aberrant GHR splicing
and may be a promising therapeutic tool. (J Clin Endocrinol Metab 95: 3542–3546, 2010)
M
olecular defects resulting in a functionless GH re-
ceptor (GHR) are the most frequent cause of con-
genital GH insensitivity (GHI) (1). Genetic analysis of a
large heterogeneous GHI population demonstrated that a
GHR A3G intronic mutation is a common cause of GHI
(2, 3). This mutation activates the recognition of a 108-
nucleotide intronic sequence as an exon, and this pseudo-
exon (dubbed 6) is included in the mature mRNA (2, 4).
The resulting mutant GHR has 36 additional amino acids
inserted in its extracellular domain that impair GHR cell
surface trafficking (Fig. 1A) (5). The GHR 6 defect is
associated with a large spectrum of GHI phenotypes, and
itispossiblethatanumberofcasesdiagnosedasidiopathic
short stature may actually have the GHR 6 defect (3).
The mainstay of the treatment of GHI is recombinant
human IGF-I. This may have serious adverse effects (6)
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recombinantGHinGH-deficientpatients,possiblydueto
its short half-life or a limited ability to reach target tissues
(7).Moreover,recombinanthumanIGF-Iiscostlyatap-
proximately $2100–4200 per month. Thus, although
IGF-I provides a solution to management of the growth
and metabolic disorders of GHI patients, a search for
more efficacious and cost-effective treatments, perhaps
targeted to the underlying molecular defect, should not
be abandoned.
Exon-skipping antisense oligonucleotides (ASOs)
are a new therapeutic tool to correct aberrant mRNA
splicing(8–14).Thesearesmallsyntheticmoleculesde-
signed to base pair to a target sequence, e.g. splice sites
on pre-mRNA. In contrast to DNA oligonucleotides or
small interfering RNA, they act by interfering with the
pre-mRNA/spliceosome interaction, causing alterna-
tive splicing and exclusion of exons. They do not cause
degradation of the mRNA either through ribonuclease
H or the RNA interference mechanism (15).
The aim of the present study was to use the exon-skip-
ping ASO approach to correct aberrant RNA splicing
caused by the GHR 6 defect.
Materials and Methods
Creation of minigenes
The wild-type minigene L1-GHR6-L2 was created by in-
serting the GHR 6 and its intronic boundaries between exons
L1andL2ofAdml-par,awellcharacterizedsplicereporter(16).
The GHR 6 was amplified from human genomic DNA, and
exons L1 and L2 were amplified from Adml-par by PCR using
FIG. 1. Results of the in vitro splicing assay on the effect of ASOs on the mutant L1-GHR6-L2 mRNA splicing. A, Top, the pseudoexon (6)i s
located in the GHR intron 6 and is normally not recognized by the splice machinery. Mutation of the last base of the 6 (6 donor splice site A to
G) leads to the recognition of the pseudoexon sequence and the inclusion of 108 additional nucleotides between exons 6 and 7 in the GHR
mRNA. The result of this mutation is the production of an abnormal GHR protein with 36 additional amino acids in its extracellular domain;
bottom, representation of the L1-GHR6-L2 mutant minigene and the ASO target positions within the minigene. The position of splice elements is
also indicated. B, Effect of ASOs, alone or in mixtures, on the mutant L1-GHR6-L2 minigene splicing. C, Dose-response analysis with ASO-3 and
-5. D, Effect of the ASO targeting the branch point (ASO-Br) on the wild-type L1-GHR6-L2 minigene. In B, C, and D, the identity of each splice
product is schematically represented next to the autoradiograph. The position of the spliced products with (294 nucleotides) and without (186
nucleotides) the 6 pseudoexon are indicated by arrows. The position of the lariats (a splicing reaction intermediate) is indicated by the asterisk.
TM, Transmembrane.
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GCAGATCAGCTT-3) and L2A (5-ATCCAAGAGTACTG-
GAAAGACCG-3). The three exons were joined by overlap ex-
tensionPCR(17).Adml-parwasthepositivecontrolforsplicing
reactions.
PCR products were cloned into the pGEM T-easy vector sys-
tem (Promega, Madison, WI) and the presence of the insert was
assessed by direct sequencing of plasmid DNA on the ABI3700
Sequencer. The mutant L1-GHR6-L2 minigene was obtained
by site-directed mutagenesis using specific primers (sequences
available on request).
ASOs
Three2-O-methylRNAASOs(Dharmacon,Lafayette,CO)
were targeted to the donor (ASO-5, 5-UUCAGUGGCUCAC-
CGAAU-3) and acceptor (ASO-3, 5-UGUGGCUGUGGUUA-
GACA-3) splice sites and the branch point (ASO-Br, 5-UUA-
GAAUUAGUUAUAUUG-3) of the mutant GHR pseudoexon
sequence(Fig.1A).Toassesstheirsequence-specificeffect,three
ASOs targeting a different gene (the insulin receptor gene:
insR11B, 5-CGCCUUUGAGGACAGAGG-3; insR113, 5-
CUGUGGAAACAAAACCAA-3; and insR115, 5-CGCA-
CAGGUGAGUCAUAC-3) were also used.
In vitro splicing assay
Wild-type and mutant DNA minigenes and Adml-par were
transcribed into radiolabeled, capped RNA. Transcription reac-
tionscontained200ngDNA,1RNAtranscriptionbuffer(Am-
bion, Austin, TX), 500 M ATP/CTP/UTP and 50 M GTP, 10
Ci[-
32P]GTP(800Ci/mmol;PerkinElmer,Norwalk,CT),1mM
7mG(ppp)G RNA cap analog (New England BioLabs, Beverly,
M A )a n d2UT 7R N APolymerase Plus (Ambion) in a final
volume of 10 l (18). Reactions were incubated for1ha t3 7C ,
gel purified on a 4% denaturing polyacrylamide gel, and resus-
pended in ribonuclease-free water.
ASOs (final concentration ranging from 0–250 nM) were in-
cubated with 20 fmol RNA at 30 C for 1 h with a splice reaction
mixture prepared as follows: 8 l HeLa nuclear extract (Cil Bio-
tech,Mons,Belgium),1l25ATP/creatinephosphatemixture
(12.5 mM ATP, 0.5 M creatine phosphate), 1 l8 0m M MgCl2,
5 l 13% polyvinyl alcohol, 1.25 l 0.4 M HEPES-KOH (pH
7.3),7lbufferD[20mMHEPES-KOH(pH8.0),100mMKCl,
0.2mMEDTA,20%glycerol,0.5mMphenylmethylsulfonylflu-
oride, 1 mM dithiothreitol], and H2Ot o2 5l (19). Control
reactions were kept on ice for the same time. At the end of the
incubation, reactions were deproteinized, precipitated, and run
on an 8% denaturing polyacrylamide gel before autoradiogra-
phy. The bands of interest were excised from the gel, retrotrans-
cribed into cDNA and PCR amplified using primers T7L1 and
L2A followed by direct sequencing.
Cell transfection
Wild-type and mutant minigenes L1-GHR6-L2 were sub-
cloned from the bacterial pGEM T-easy vector into the mam-
malian pcDNA3.1 vector.
HEK293cellsweremaintainedinDMEM(Sigma-Aldrich,St.
Louis, MO) with 10% fetal bovine serum (Sigma-Aldrich) at 37
C under 5% CO2. Cells were transiently transfected at 50%
confluency with the mutant pcDNA3.1 L1-GHR6-L2 plasmid
(50 ng) and different concentrations of ASOs (final concentra-
tion ranging from 0–250 nM) using Lipofectamine 2000 (In-
vitrogen, Carlsbad, CA). Forty-eight hours after transfection,
cells were harvested, RNA extracted, and reverse transcribed,
andcDNAwasamplifiedinthepresenceof0.5Ci[-
32P]dCTP
with primers T7L1 and L2A in a 12.5-l PCR. PCR products
were separated on an 8% nondenaturing polyacrylamide gel be-
fore autoradiography and quantitation on a PhosphorImager
(Molecular Dynamics, Sunnyvale, CA). The percentage of alter-
native splicing was calculated as the ratio of isoform to total of
all isoforms, and results are presented as mean  SEM of at least
three separate experiments.
Results
ASO-3 corrects aberrant splicing caused by the
GHR 6 in the in vitro splicing assay
Each ASO was initially tested at a 250 nM concentra-
tion.ASO-3induced6skippingfromthemRNA,asdem-
onstrated by the absence of the 294-nucleotide band cor-
responding to the L1-GHR6-L2 mRNA and the
appearance of the 186-nucleotide band corresponding to
spliced exons L1 and L2. ASO-5 produced modest 6
skipping, whereas ASO-Br had no effect (Fig. 1B). We
tested whether the combined targeting of two splice sites
couldbemoreeffectivethantargetingofasinglesplicesite.
Forthispurpose,twoASOsatafinalconcentrationof125
nM each were used in the same reaction. Mixtures of
ASO-3and-5andASO-3and-Brcausedmodestskipping
of 6. Almost no 6 skipping was seen for the mixture
ASO-5 and -Br (Fig. 1B).
ASO-3 and ASO-5, which had produced 6 skipping,
were further tested by titration between 10 and 250 nM.
ASO-3 induced complete 6 skipping from the mRNA at
concentrations over 100 nM, whereas its effect was ex-
tremely weak and almost negligible at 50 and 10 nM.
ASO-5 produced modest 6 exclusion from the mRNA,
with the maximal effect seen at over 100 nM (Fig. 1C).
Because ASO-Br reduced the efficacy of ASO-3 and -5,
itwasusedwiththewild-typeL1-GHR6-L2minigeneto
testwhetheritcouldactasanenhancerof6inclusion.No
band of 294 nucleotides corresponding to the L1-
GHR6-L2 mRNA was detected (Fig. 1D).
Totestthesequence-specificeffectofASO-3,threeneg-
ative control ASOs not targeting the minigene (ASO
insR11B, -113, and -115) were used at a concentration of
250 nM.N o6  skipping was seen (data not shown).
ASO-3 is the most effective in correcting GHR 6
aberrant splicing in HEK293 cells
The three ASOs were transfected with the pcDNA3.1
L1-GHR6-L2 mutant plasmid in HEK293 cells. Two
ASO concentrations (250 and 125 nM) which were most
effective in inducing 6 skipping in vitro were tested.
ASO-3 induced the most skipping of 6, 80.7  13.7%
3544 David et al. Repair of GHR 6 Pseudoexon using ASOs J Clin Endocrinol Metab, July 2010, 95(7):3542–3546(250 nM) and 97.3  1.3% (125 nM), whereas ASO-5
produced modest 6 skipping, 48.6  13.4% (250 nM)
and 47.4  12.1% (125 nM). ASO-Br was the least effec-
tive at 5.2  2.4% (250 nM). The mixture of ASO-5 and
-3resultedin38.521.7%skipping,whereasthemixture
of ASO-5 and -Br and ASO-3 and -Br resulted in 13.5 
6.3 and 6.1  3.5% skipping, respectively (Fig. 2).
Discussion
The GHR 6 mutation A3G is a frequent cause of con-
genital GHI due to the presence of a defective GHR (3).
The phenotypic variability associated with this mutation
may reflect the partial exclusion/inclusion of this exon in
patients,whichmaybeindicativeoftheborderlinenature
ofthesplicingdeterminantsinthissequence.Ifso,thismay
indicate the potential for this site to be corrected. In this
study, we show that ASOs are effective for this purpose,
both in vitro and in a cell transfection system.
Exon-skippingASOsarecurrentlyusedtocorrectsplic-
ing in neurodegenerative diseases and hematopoietic dis-
orders,withpromisingresultsinvitroaswellasinvivo(8,
10, 14, 20). These ASOs alter mRNA splicing either by
physically interfering with the recognition of the splice
elements (splice sites, branch points, or enhancers) by the
spliceosome or by inducing a secondary structure that fa-
vors exon skipping (20). This study tested the efficacy of
ASOsinrestoringcorrectGHRsplicing.AnASOdirected
againstthemutant5splicesiteofthe6wastestedalong-
side ASOs targeted against two other splicing elements:
the 3 splice site and the branch point. The efficacy and
optimal conditions of the three ASOs were first tested us-
ing the in vitro splicing assay and then
inHEK293cells.Asexpected,theeffect
of the ASOs was sequence specific and
dose dependent, with an optimal effect
seen at concentrations from 100–250
nM. Surprisingly, the most effective
ASO, both in vitro and in HEK293
cells, targeted the 3 splice site. The
ASO against the 5 splice site, adjacent
to the 6 mutation, showed modest ef-
ficacy in restoring correct splicing. Dif-
ferent accessibilities of the 5 vs. the 3
splice site to ASOs in the two cell lines
used in this study (HeLa cells for the in
vitro splicing assay and HEK293 cells
for cell transfection studies) may ex-
plain the superior efficacy of the ASO
targeting the 3 splice site compared
withtheASOtargetingthe5splicesite.
It is also possible that ASO-5 interferes
with the binding of the 6 splicing silencer hnRNP E1,
whichbindsnearbywithinpositions79–98of6,encour-
aging 6 inclusion and partially reversing the exon-skip-
ping effect (4). Demonstration of this effect is worthy of
investigation in future work. However, the aim of this
study was to explore the feasibility of using ASOs for cor-
recting aberrant splicing, rather than to explore the mo-
lecular mechanisms by which ASOs work, among which
interference with hnRNP E1 function is one possible
mechanism.
Although some studies have suggested that targeting
more than one splice element can be more effective than
targeting single elements (20), this study demonstrated
that simultaneous use of two ASOs was less effective and
attenuatedtheeffectofindividualASOs,bothinvitroand
in cellulo. This was particularly evident in the case of the
ASO targeting the branch point (ASO-Br), which, used
together with other ASOs, significantly blunted their ef-
fect. The mechanism responsible for this phenomenon re-
mainsunknown.ItisunlikelythatthisisduetoalowASO
concentration, because the final concentration of each
ASO in the combination experiments was 125 nM, the
samedosethatwaseffectiveininducing6skippingwhen
ASO-3 and -5 were used alone. A promoting effect of the
ASO-Br on GHR 6 inclusion also appears unlikely.
When tested in vitro on the wild-type minigene, ASO-Br
did not result in the inclusion of the 6 in the spliced
mRNA.
Two limitations of this study include, first, the lack of
data on the effect of ASOs on cells from GHI patients
expressingthemutantGHR.Availabilityofpatientcellsin
future studies will allow us to demonstrate in vivo the
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FIG. 2. Effect of ASOs in HEK293 cells. A, HEK293 cells were transfected with plasmid
pcDNA3.1 L1-GHR6-L2 carrying the 6 mutation A3G and with one or more ASOs. One
representative example of three separate experiments is presented. The position of the bands
corresponding to the mRNA product with (294 nucleotides) or without (186 nucleotides) the
GHR 6 is indicated. B, Quantitative data are presented as mean  SEM, indicated by the error
bar, of at least three separate experiments.
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functional activity. Second, although our results suggest a
sequence-specificeffectofASO-3,itmaybethatthisASO
also blocks additional splice sites similar to the GHR 6
butlocatedinotherpre-mRNAs.Beforedevelopmentasa
potential therapy, nonspecific effects on alternative splic-
ing will need to be excluded.
Splice defects are a common cause of genetic diseases
and represent approximately 20% of GHR defects caus-
ing GHI (1). In this study, we tested the potential thera-
peutic application of ASOs in the correction of aberrant
GHR splicing caused by the 6 defect. This mutation is a
commoncauseofGHIresultingfromafunctionlessGHR.
Itisassociatedwithabroadrangeofphenotypesandmay
also be present in patients diagnosed as idiopathic short
stature. Because of its clinical importance as well as its
peculiar molecular basis, the 6 defect was an ideal can-
didate for studying the effect of ASOs in inducing exon
skipping. Nevertheless, other splice defects in the GHR,
such as the dominant-negative mutations around exon 9
splice sites (1), may also be amenable to correction with
theASOapproach.Inthesecases,theuseofASOstoblock
the exon 9 splice site on the mutant allele may favor GHR
mRNA splicing from the wild-type allele, thus restoring
the normal phenotype.
In conclusion, the use of exon-skipping ASOs for re-
storingaberrantsplicingcausedbytheGHR6mutation
appearspromising,andresultsfromthisstudycouldform
the basis for future gene therapies in patients with GHI
caused by this defect.
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